€120m · Series D+ · Healthtech · Basel, Switzerland
Basel-based Nouscom, a clinical-stage biotech developing neoantigen-targeted cancer immunotherapies, has closed €120m in an oversubscribed Series D co-led by M Ventures and Revelation Partners. The company said the capital will take its lead programme, NOUS-209, into a global registration-enabling trial for cancer interception in people with Lynch syndrome.
Financing the step from signal to pivotal evidence
NOUS-209 is an investigational, off-the-shelf immunotherapy designed to train the immune system to recognise shared neoantigens associated with mismatch-repair-deficient tumours. Rather than treating only established disease, Nouscom is testing whether immune responses can stop precancerous changes from progressing in people with an inherited high cancer risk. The programme has received FDA Fast Track designation, but it remains investigational and has not been approved.
The financing arrives alongside longer-term Phase 1b/2 data. Nouscom reported that all evaluable participants remained free of advanced adenomas and colorectal cancer at years one and two, with 43 and 17 evaluable participants respectively. Those company-presented results are an encouraging early signal, not proof of efficacy; the planned registration-enabling trial must test the approach at a scale and standard capable of supporting a regulatory decision.
That makes the round’s commercial logic unusually concentrated. The capital is not spread across a broad product roadmap: it is intended to buy the trial execution, follow-up and regulatory work needed to turn a promising prevention signal into evidence for an approvable medicine. For investors, value creation therefore depends on enrolment, consistent dosing and durable clinical outcomes, rather than near-term customer acquisition.
A syndicate built around clinical execution
New investors Angelini Industries, the European Investment Bank through Aurea, and Neva SGR joined the round, while Nouscom’s existing life-sciences backers also participated. Fierce Biotech reported that the financing is aimed at the pivotal programme, reinforcing that this is a late-stage development bet rather than a platform-only wager.
The central execution challenge is the same feature that makes cancer interception attractive: success must be demonstrated before disease develops. That requires long follow-up and clinically meaningful endpoints in a high-risk population. The €120m round gives Nouscom resources to pursue that evidence, but the registration-enabling trial will determine whether NOUS-209 can move from an early immunological and clinical signal to a viable preventive treatment.
Sources checked:
Nouscom announcement · Fierce Biotech reporting · Tech.eu Funding Explorer deal
